// App-Quantinova.ai

AB0271 : BENEFICIAL EFFECT OF ANTI-TNF THERAPY IN THE LIPOPROTEIN ATHEROGENIC RISK PROFILE IN COMPARISON WITH DMARD STANDARD THERAPY IN RA PATIENTS

Researchers

Presenter

  • J. Calvo Alen

Principal Investigators

  • C. Baamonde

  • M. Agudo

  • T. Ruiz-Jimeno

  • J. Gomez-Gerique

Medical Centers

  • Hematology, Hospital Universitario Marques de Valdecilla, Santander, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Paraoxonase 1

  • Proprotein convertase subtilisin/kexin type 9

  • High sensitivity C-reactive protein

Drug/Treatment

  • Methotrexate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved